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Type 1 diabetes (T1D) is largely considered an autoimmune disease leading to the
destruction of insulin-producing pancreatic b cells. Further, patients with T1D have 3–4-
fold increased risk of developing micro- and macrovascular complications. However, the
contribution of immune-related factors contributing to these diabetes complications are
poorly understood. Individuals with long-term T1D who do not progress to vascular
complications offer a great potential to evaluate end-organ protection. The aim of the
present study was to investigate the association of inflammatory protein levels with
vascular complications (retinopathy, nephropathy, cardiovascular disease) in individuals
with long-term T1D compared to individuals who rapidly progressed to complications. We
studied a panel of inflammatory markers in plasma of patients with long-term T1Dwith (n =
81 and 26) and without (n = 313 and 25) vascular complications from two cross-sectional
Scandinavian cohorts (PROLONG and DIALONG) using Luminex technology. A subset ofn.org October 2020 | Volume 11 | Article 5754691
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Frontiers in Endocrinology | www.frontiersiPROLONG individuals (n = 61) was screened for circulating immune cells using multicolor
flow cytometry. We found that elevated plasma levels of soluble interleukin-2 receptor
alpha (sIL-2R) were positively associated with the complication phenotype. Risk carriers of
polymorphisms in the IL2RA and PTPN2 gene region had elevated plasma levels of sIL-
2R. In addition, cell surface marker analysis revealed a shift from naïve to effector T cells in
T1D individuals with vascular complications as compared to those without. In contrast, no
difference between the groups was observed either in IL-2R cell surface expression or in
regulatory T cell population size. In conclusion, our data indicates that IL2RA and PTPN2
gene variants might increase the risk of developing vascular complications in people with
T1D, by affecting sIL-2R plasma levels and potentially lowering T cell responsiveness.
Thus, elevated sIL-2R plasma levels may serve as a biomarker in monitoring the risk for
developing diabetic complications and thereby improve patient care.Keywords: cardiovascular disease, Cluster of Differentiation 25 (CD25), diabetes complications, nephropathy,
regulatory T cells, retinopathy, sIL-2RINTRODUCTION
Type 1 diabetes (T1D) is characterised by T cell mediated
autoimmune destruction of insulin-producing pancreatic b cells
(1, 2), causing T1D individuals to become insulin-dependent
throughout their life (3). Most of the patients with T1D develop
macrovascular complications such as cardiovascular disease
(CVD), and microvascular complications, including proliferative
diabetic retinopathy (PDR), chronic kidney disease (CKD), and
peripheral neuropathy (PN) (4). The rising prevalence of T1D and
its associated long-term vascular complications clearly confer a
humanistic (5) and socio-economic burden (6). Vascular
complications in T1D individuals are a common cause of
mortality related to end-organ damage as compared to the non-
diabetic population (4, 7). Remarkably, few patients with T1D do
not progress to these vascular complications despite long disease
duration and chronic hyperglycaemia, and therefore exert great
potential to evaluate end-organ protection (8).
Although T1D individuals with complications show
considerable derangement in immunological processes like
having elevated concentrations of C-reactive protein (CRP), a
marker of inflammation, proinflammatory cytokines interleukin-6
(IL-6), and tumor necrosis factor alpha (TNF-a) as compared to
individuals without complications (9), the extent of contribution
of immunological factors to the development of vascular
complications in patients with T1D is poorly understood.
Over the past decades, both genetic (10, 11) and
immunological (12, 13) studies revealed IL-2 receptor (IL-2R)
and its downstream signalling pathways as central players in the
pathogenesis of T1D (14). Upon binding of IL-2 to its receptor
IL-2R, a cascade of signalling events is initiated. These events are
negatively regulated by the ubiquitously expressed phosphatase
tyrosine-protein phosphatase non-receptor type 2 (PTPN2) (14,
15). IL-2 signalling is critical for the function of regulatory T cells
(Tregs), a type of suppressive immune cell, which plays an
indispensable role in maintaining immune homeostasis (16)
and prevention of autoimmune diseases (17, 18). In addition,n.org 2elevated levels of soluble IL-2R alpha (sIL-2R; alternative: IL-
2RA, CD25) have been reported to be an important factor in the
development of diabetic retinopathy in non-insulin-dependent
diabetes patients (19) and coronary artery calcification in T1D
patients (20). However, a limitation of both studies was that the
patient group without complications had a considerably shorter
diabetes duration compared to the patient group with the
respective complications. Therefore, some of the patients in the
complications-free group could have later progressed to vascular
complications. Furthermore, Colombo et al. (2019) reported that
elevated levels of sIL-2R were associated with a decline in
estimated glomerular filtration rate (eGFR) in T1D patients (21).
The aim of the present study was to evaluate plasma levels of
inflammatory proteins including but not limited to sIL-2R in
long-term T1D individuals with and without vascular
complications. Additionally, a subset of patients was screened
for circulating immune cells to investigate cell populations
associated with developing vascular complications in T1D
individuals. Finally, plasma sIL-2R levels were correlated to
genetic risk variants in IL2RA and PTPN2.METHODS
Study Design
This immunological investigation forms a part of the PROtective
genetic and non-genetic factors in diabetic complications and
LONGevity (PROLONG) study, which was launched to identify
protective factors against complications in long-term T1D
individuals. Patients were recruited from seven departments of
endocrinology/diabetes outpatient clinics in Sweden and at the
Steno Diabetes Center in Denmark. As an extended collaborative
effort, we included T1D individuals from a Norwegian cohort,
DIALONG. The DIALONG study also included non-diabetic
spouses or friends as a control group.
We classified T1D patients into two groups comparing their
diabetes complications status. Non-progressors (NP) wereOctober 2020 | Volume 11 | Article 575469
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having progressed to any of the specified complications. Patients
who progressed to complications within 25 years of T1D
diagnosis were defined as rapid progressors (RP). We defined
late progressors (LP) as T1D patients that did progress to
complications >25 years post diagnosis. For this study RPs and
LPs were pooled into one group referred to as progressors (P).
In PROLONG, PDR was defined by the presence of
proliferative retinopathy in at least one eye, confirmed laser
treatment (panretinal photocoagulation) or blindness. For CKD
we used the following inclusion criteria: presence of nighttime
albuminuria over 200 µg/min, macroalbuminuria over 300 mg/g
or a documented diabetic kidney disease diagnosis. None of the
PROLONG participants were treated with SGLT2 inhibitors.
Documented events including non-fatal myocardial infarction,
stroke (haemorrhagic or ischemic), balloon angioplasty, or
coronary artery bypass were defined as CVD. There was
limited information on CVD, as the original focus of
PROLONG was on microvascular complications.
In DIALONG (22) macro- and microvascular complications
were defined using similar criteria as in PROLONG. PDR was
defined by the presence of proliferative retinopathy or blindness.
Laser treatment was not used as criteria here as it was not
exclusively applied to proliferative retinopathy in this study.
CKD was adjusted to include patients with persistent
microalbuminuria or proteinuria. None of the DIALONG
participants were treated with SGLT2 inhibitors. CVD was
defined by stroke or myocardial infarction events, coronary
artery bypass or percutaneous coronary intervention (PCI),
diagnosed peripheral vascular disease or heart failure.
The regional ethical committees approved the studies
(PROLONG: Denmark H-2-2013-073, Sweden 777/2009,
Norway 2019/1324; DIALONG: Norway 2014/851) and all
participants provided written informed consent.
Blood Sampling
Collected EDTA plasma was aliquoted and stored at -80°C for ~6
years (PROLONG) and ~3 years (DIALONG).
For peripheral blood mononuclear cells (PBMCs) isolation,
peripheral blood from patients with T1D (PROLONG) with and
without complications was collected in CPT tubes (BD
Vacutainer) at the Steno Diabetes Center, Denmark. PBMCs
were subsequently isolated by density gradient centrifugation
and cryopreserved in human AB serum containing 10% DMSO
at -80°C for ~5 years.
Cytokine Analysis
In DIALONG, plasma cytokines were measured in 79 individuals
using an Invitrogen™ Human Cytokine 30-Plex kit
(LHC6003M, Thermo Fisher Scientific) according to the
manufacturer’s instructions. The following adjustments were
made to the protocol: (a) one additional standard was included
in the serial dilution, making the standard range from 1:3 to
1:2,187; (b) undiluted plasma samples that underwent one
freeze-thaw cycle were measured. The following biomarkers
were detected in >90% of samples (CCL11, IFN-a, IL-12, sIL-2R,
CXCL10, CCL2, CCL3, CCL4 and CCL5), whereas others wereFrontiers in Endocrinology | www.frontiersin.org 3only detected in 40–75% (FGF basic, G-CSF, HGF, IL-13, IL-1RA,
CXCL9, VEGF) and <17% of patients (EGF, IFN-g, IL-10, IL-15,
IL-17A, IL-1b, IL-2, IL-4, IL-6, TNF-a). GM-CSF, IL-5, IL-7, and
IL-8 were not detected in any samples.
In PROLONG, we used a custom-designed ProCartaPlex™
Human Cytokine Panel (sIL-2R, CCL2, CCL11, IFN-a; Thermo
Fisher Scientific) according to manufacturer’s instructions to
measure plasma cytokines. The following adjustments were
made to the protocol: (a) one additional standard was included
in the serial dilution, making the standard range from 1:4 to
1:32,768 (in pg/ml: sIL-2R 10.06–82,425; CCL2 0.45–3,650;
CCL11 0.07–550; IFN-a 0.08–625); (b) undiluted plasma
samples that underwent one freeze-thaw cycle were measured.
Data was acquired on a Luminex® 100™, counting 3,000
(DIALONG) and 600 (PROLONG) beads per well. The five-
parameter logistic algorithm [weighted by 1/y, (V2.4)] and raw
median fluorescence intensity values were used for the creation
of standard curves.
Genetic Analysis
The DNA samples in the PROLONG study were genotyped
using InfiniumCoreExome-24v1-1 array. Standard quality
control steps for GWAS were performed. Imputation was
performed using Michigan Imputation Server (https://
imputationserver.sph.umich.edu/index.html) using Haplotype
Reference Consortium Release 1.1 (HRC.r1-1, GRCh37) as a
reference panel. Variants with minor allele frequency (MAF)
<5% were excluded before imputation. In the present study, we
extracted the region for the IL2RA (Chromosome 10: 6,052,652-
6,104,288, build GRch37) and PTPN2 gene (Chromosome 18:
12,785,477-12,929,642, build GRch37) for analysis. Only variants
with imputation quality R2 >0.4 and with MAF >5% were
included in the analysis.
Principal component analysis (PCA) was performed on
pruned, directly genotyped SNPs using 1,000 Genomes’
reference panel version 5A. Population outliers were examined
based on visual inspection of PC1 and PC2, and outliers were
excluded from the further analysis. Only individuals with
complete data on sIL-2R, sex, complication group, HbA1c and
age at visit were included. In total, there were 330 individuals
analyzed. We used linear regression adjusted for sex, age, and
complication group to identify associations between genetic
variants and log-transformed plasma levels of sIL-2R.
Antibodies Used for Flow Cytometry
We designed two flow cytometry panels using multiple
fluorochrome-conjugated antibodies. Panel 1 includes 14
markers (14 colors), which can discriminate the main
mononuclear immune cell types (B cells, T cells, NK cells,
monocytes, dendritic cells), and endothelial progenitor cells.
Panel 2 includes 16 markers (15 colors) and focuses
specifically on different types of T cells. Pacific orange dye
(250 ng/ml; Life Technologies) was used as a live/dead marker
in both panels. The monoclonal antibodies used in the two
panels during the flow cytometry protocol are listed in
Supplementary Table 1.October 2020 | Volume 11 | Article 575469
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Before staining, cryopreserved PBMCs were rapidly thawed
using a water bath set to 37°C and washed once in cold PBS
(without calcium and magnesium, Lonza) containing 5% AB
serum and Benzonase® Nuclease (1:10,000; Merck Millipore) by
centrifugation at 450 x g for 5 min at 4°C. The PBMCs were then
resuspended in cold PBS and stained with pacific orange (250 ng/
ml; Life Technologies) for 20 min on ice in the dark. Following
live/dead staining, cells were washed once, taken up in cold
FACS-buffer (PBS containing 0.5% BSA) and incubated with 2 µl
Fc receptor block (Miltenyi Biotec) per 1 x 106 cells for 10 min on
ice. Cells were then subdivided into two parts and incubated for
30 min on ice in the dark with the respective antibody staining
panel. The samples were subsequently washed once and re-
suspended in FACS-buffer prior to analysis at the flow cytometer.
Flow Cytometry Analysis
Samples were acquired on a LSRI Fortessa flow cytometer (BD
Biosciences) with BD FACSDiva™ Software (BD Biosciences) at
the Bergen Flow Cytometry Core Facility, University of Bergen,
Norway. The flow cytometer was equipped with 407, 488, 561,
and 635 nm lasers, and emission filters for PerCP-Cy5.5 (Long
Pass (LP): 685, Band Pass (BP): 695/40), Alexa Fluor 488 (LP:
505, BP: 530/30), PE-Cy7 (LP: 750, BP: 780/60), PE (LP: -, BP:
582/15), APC (LP: -, BP: 670/14), Pacific blue (LP: -, BP: 450/50),
Pacific orange (LP: 570, BP: 585/42), and BV786 (LP: 750, BP:
780/60). The cytometer was routinely calibrated with BD
cytometer setup and tracking beads (BD Biosciences). An
average of 138,635 (panel 1) and 122,287 (panel 2) events were
recorded in the intact single cell gate and mean percentage of live
cells was 98 and 96% for panels 1 and 2, respectively. Flow
cytometry data was analyzed in FlowJo™ 10 (Tree Star).
Compensation beads (eBioscience) stained with the respective
antibody were used as controls to calculate the compensation
matrix. The representative gating strategies for both panels are
shown in Supplementary Figures 1 and 2 and were validated
with the unsupervised gating method using the tSNE algorithm
(Supplementary Figures 3B, C). For accurate gating,
fluorescence minus one (FMO) controls were run regularly for
both panels.
Statistical Analysis
sIL-2R was log2 transformed prior to analysis. Values above the
ordinary range were removed by biological consideration and
literature review. The Mann-Whitney U test was used in the
comparison between the complication groups in the analyses of
plasma cytokines. To evaluate the association between two
variables we used the Pearson correlation formula. In flow
cytometry analysis, multiple linear regression was applied and
adjusted for the age and sex covariates. Differences were
considered statistically significant when p <0.05. The study was
of exploratory nature and hence no correction was made for
multiple comparisons. Comparisons between patient groups,
correlations and the production of associated graphs were done
using R Studio (Version 1.1.456). Figures were arranged in
Adobe Illustrator CS6.Frontiers in Endocrinology | www.frontiersin.org 4RESULTS
Elevated sIL-2R in T1D Individuals
Baseline characteristics of DIALONG study participants are
given in Table 1. There were 26 T1D individuals with vascular
complications (progressor, P), of whom 10 had CKD, 11 had
CVD, and all apart from one had PDR. As the matching groups
we included 25 T1D individuals without any vascular
complications (non-progressors, NP) and 28 healthy controls.
In brief, progressors had significantly higher BMI and slightly
elevated HbA1c. The groups were balanced regarding age, sex,
and eGFR.
There was a significant increase of sIL-2R (p = 0.0011) in T1D
as compared to healthy individuals (Figure 1A). The increase
was gradual in relation to vascular complication status, being
highest in the progressor group (Control vs. NP: p = 0.014;
Control vs. P: p = 0.0021; NP vs. P: p = 0.47) (Supplementary
Figure 4A). None of the other analyzed cytokines showed
significant differences between the T1D groups in relation to
their complication status (Supplementary Figure 5A). An
overview over the detection rate for each investigated cytokine
is provided in Supplementary Figure 5B.
To investigate complication status further, we stratified
progressors into those with CKD, CVD, or PDR. These
analyses revealed that progressors with CVD had significantly
elevated sIL-2R plasma levels (p = 0.029) as compared to NPs
(Supplementary Figure 4B). Plasma sIL-2R was slightly
increased in progressors with CKD (p = 0.19) as compared to
NPs (Supplementary Figure 4C), and sIL-2R correlated
negatively with eGFR (T1D: R = -0.42, p = 0.0037)
(Supplementary Figure 4D). Adjusting for eGFR did not
change the observed result with CKD (p = 0.35). Plasma sIL-
2R was elevated in progressors with PDR compared to NPs (p =
0.36) (Supplementary Figure 4E). Monocyte chemotactic
protein-1 (CCL2, alternative: MCP-1) plasma levels were
significantly higher in progressors with CKD (p = 0.021) and
CVD (p = 0.013) compared to NPs (Supplementary Figures 4F,
G). CCL2 was slightly elevated in progressors with PDR
compared to NPs (p = 0.09) (Supplementary Figure 4H).
Elevated sIL-2R in T1D Individuals
with Vascular Complications
In order to confirm our cytokine findings in DIALONG in a
larger and independent cohort, we measured 4 nominally
associated cytokines (sIL-2R, CCL2, CCL11, IFN-a) in
plasma from PROLONG patients with T1D with and without
complications (n = 394). Clinical characteristics for this cohort
are summarized in Table 2. We included 81 patients with T1D
with vascular complications (progressors, P), of whom 40 had
PDR, 58 had CKD, and on 2 we had information on CVD.
Those individuals were compared to 313 T1D individuals
without any vascular complications (non-progressors, NP).
Progressors were significantly younger in age, displayed
significantly higher BMI and HbA1c and lower eGFR and
diabetes duration compared to NPs. The groups were
balanced regarding sex.October 2020 | Volume 11 | Article 575469
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CCL2, CCL11), while IFN-a was only detected <16% of samples
(Supplementary Figure 6B). We observed a significant increase
of sIL-2R (p = 0.0064) in progressors compared to NPs (Figure
1B). This observed difference was even more pronounced (p =
0.00084) when comparing NPs with progressors with PDR
(Figure 1C). Additionally, sIL-2R was slightly increased in
patients with CKD (p = 0.077) compared to NPs (Supplementary
Figure 6C), and sIL-2R correlated negatively with eGFR (R = -0.12,
p = 0.025) (Supplementary Figure 6D). Adjusting for eGFR using
linear regression, resulted in a significant increase in sIL-2R between
progressors with CKD and NPs (p = 0.041). Comparisons for CVD
could not be made due to the small sample size of progressors with
information on CVD (n = 2). As observed in the DIALONG cohort,
there was no significant difference between the complication groups
in CCL2 (p = 0.46), CCL11 (p = 0.25), and IFN- a (p = 0.40)
(Supplementary Figure 6A). In PROLONG, CCL2 was not
elevated in progressors with CKD (p = 0.39) (Supplementary
Figure 6E). Progressors with PDR and NPs showed similar levels
of CCL2 (p = 0.97) (Supplementary Figure 6F).Association of sIL-2R Levels With IL2RA
and PTPN2 Gene Variants
To identify associations between genetic variants in IL2RA and
plasma levels of sIL-2R, we used linear regression adjusting for
sex, age, and group. Plasma levels of sIL-2R were significantly
associated with 68 SNPs in the IL2RA gene (Table 3), with
rs12722489 showing the statistically strongest association (p =
5,19 × 10-7). Two of our identified SNPs are located in exon 8,Frontiers in Endocrinology | www.frontiersin.org 5namely rs12722606 and rs12722605. The majority of the
associated SNPs (n = 51) are located in the large intron 1 area
of IL2RA.
Furthermore, sIL-2R levels were significantly associated with
53 intronic SNPs in the PTPN2 gene region (Table 4). The
variant rs12971201 showed the strongest association with plasma
sIL-2R (p = 1.09 × 10-3). When we conditioned this analysis for
the T1D-associated SNP rs2104286 in IL2RA, we could still
identify 42 PTPN2 variants to be independently associated with
sIL-2R (Table 4). Here rs592390 had the strongest association
with plasma sIL-2R (p = 2.16 × 10-3).
Cell-Surface Marker Analysis on PBMC
of T1D Individuals
Our flow cytometry panels enabled us to investigate a range of
different cell populations, which are summarized in
Supplementary Figure 3A. The applied gating strategies are
provided in Supplementary Figure 1 and 2. Baseline
characteristics for this subset of PROLONG patients are
provided in Table 2. In total, we performed flow cytometry
analysis on 61 T1D samples, of which 17 were from progressors.
The groups were balanced regarding age and sex.
We identified a significant decrease of CD8+ naïve T cells
(CD3+CD8+CD45RA+CCR7+CCR5-) (p = 0.0046) and increase of
CD8+ effector T cells (CD3+CD8+CD45RA+CCR7-) (p = 0.070) in
progressors compared to NPs (Figures 2A, B). Furthermore,
progressors had significantly increased CD4+ effector T cells
(CD3+CD4+CD45RA+CCR7-) (p = 0.045) and decreased CD4+
naïve T cells (CD3+CD4+CD45RA+CCR7+CCR5-) (p = 0.14)
compared to NPs (Figures 2C, D). To summarize, we observedTABLE 1 | Clinical characteristics of the DIALONG study participants.
Cohort Healthy control NP Progressors p-value
N 28 25 26
Age (years) 62.2 ± 6.3 63.1 ± 6.5 62.2 ± 6.5 ns
BMI (kg/m3) 26.6 ± 4.2a 25.1 ± 3.3 27.3 ± 3.9 3.66 × 10-2
Diabetes duration (years) NA 50.5 ± 3.4 51.3 ± 5.1 ns
Age at diagnosis (years) NA 12.6 ± 5.6 10.8 ± 6.5 ns
Sex (% female) 57% 48% 54% ns
HbA1c (%) 5.5 ± 0.2 7.3 ± 0.8 7.6 ± 0.8 ns
GAD AA positive (%) 7% 29%b 32%c ns
IA-2 AA positive (%) 4% 8%b 16%c ns
Insulin AA positive (%) 0% 71%b 68%c ns
ZnT8 AA positive (%) 0% 4%b 8%c ns
AA positive (%) 7% 75%b 80%c ns
eGFR (ml/min/1.73 m3) 83.4 ± 16.4 85.4 ± 15.1 78.5 ± 26.1 ns
C-peptide (nmol/L) 718.3 ± 225.3 undetectable undetectable ns
CRP (mg/L) 1.8 ± 2.3d 3.3 ± 6.1e 3.0 ± 3.3e ns
Statins 6 (21%) 9 (36%) 17 (65%) 3.87 × 10-2
Beta-blocker 1 (4%) 2 (8%) 10 (38%) 1.16 × 10-2
ACEi/ARB 6 (21%) 7 (28%) 19 (73%) 1.49 × 10-3
Antiplatelet agent 6 (21%) 1 (4%) 14 (54%) 1.16 × 10-4
Loop diuretics 0 (0%) 1 (4%) 7 (27%) 2.69 × 10-2
PDR/CKD/CVD (n) NA NA 25/10/11October 2020 | Volume 11 | ArtValues for continuous variables are presented as mean ± SD. P-values were calculated between NPs and progressors by Mann–Whitney U test. NP, non-progressor; BMI, body mass
index; HbA1c, haemoglobin A1c; GAD, glutamic acid decarboxylase; AA, autoantibody; IA2, islet cell antigen-2; ZnT8, zink transporter 8; eGFR, estimated glomerular filtration rate;
C-peptide, connecting peptide; CRP, C-reactive protein; ACEi, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; PDR, proliferative diabetic retinopathy; CKD, chronic
kidney disease; CVD, cardiovascular disease.
an = 27, bn = 24; cn = 25, dn = 21, en = 20.icle 575469
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Cohort Cytokine assay Flow cytometry
NP Progressors p-value NP Progressors p-value
n 313 81 44 17
Age (yrs.) 58.1 ± 10.6 44.6 ± 13.7a 1.08 × 10-13 50.6 ± 7.2 50.8 ± 15.5 ns
BMI (kg/m3) 24.8 ± 3.7b 26.4 ± 4.7 3.94 × 10-3 25.3 ± 4.2 25.3 ± 4.7 ns
Diabetes duration (years) 40.6 ± 8.6 22.4 ± 8.3 <2.2 × 10-16 37.7 ± 5.1 29.9 ± 13.4 9.49 × 10-3
Age at diagnosis (years) 17.5 ± 9.9 22.0 ± 14.4a ns 12.9 ± 6.0 20.9 ± 13.2 4.63 × 10-2
Sex (% female) 58% 53% ns 59% 53% ns
HbA1c (%) 7.6 ± 0.9 8.9 ± 1.5 3.33 × 10-14 7.4 ± 0.9 8.5 ± 0.8 6.35 × 10-5
GAD AA positive (%) 50%c 68% 8.15 × 10-3 50%d 90%e 2.41 × 10-2
eGFR (ml/min/1.73 m3) 90.2 ± 15.5 97.4 ± 30.8f 3.66 × 10-3 94.6 ± 16.6 93.3 ± 29.7 ns
C-peptide (nmol/L) 0.03 ± 0.07g 0.03 ± 0.05h ns 0.01 ± 0.02i 0.02 ± 0.01j 3.37 × 10-2
PDR/CKD/CVD (n) NA 40/58/2 NA 10/12/0Frontiers in Endocrinology | www.frontiersin.org 6 October 2020 | Volume 11 | ArtValues for continuous variables are presented as mean ± SD. P-values were calculated by Mann–Whitney U test. NP, non-progressor; BMI, body mass index; HbA1c, haemoglobin A1c;
GAD, glutamic acid decarboxylase; AA, autoantibody; eGFR, estimated glomerular filtration rate; C-peptide, connecting peptide; PDR, proliferative diabetic retinopathy; CKD, chronic
kidney disease; CVD, cardiovascular disease.
an = 77; bn = 308; cn = 303; dn = 40; en = 10; fn = 76; gn = 296; hn = 68; in = 35; jn = 7.A B
C
FIGURE 1 | Elevated plasma levels of sIL-2R in patients with type 1 diabetes (T1D). (A) Patients with T1D from the DIALONG cohort had significantly elevated sIL-
2R plasma levels compared to healthy controls. (B) In PROLONG, sIL-2R plasma levels were significantly increased in T1D with vascular complications (progressors,
P) compared to T1D patients without complications (non-progressors, NP). (C) PROLONG progressors with proliferative diabetic retinopathy (PDR) showed
significantly higher sIL-2R plasma levels compared to progressors with other vascular complications. (The Mann-Whitney U test was used in the comparison
between the different groups. **p < 0.01 and ***p < 0.001).icle 575469
Keindl et al. Increased sIL-2R in T1D ComplicationsTABLE 3 | Imputed IL2RA genotypes and their significant associations with sIL-2R in plasma.
Chr SNP bp* Intron/Exon A1 n Beta (95% CI) p-Value
10 rs12722489 6102012 Intron 1 T 330 −0.28 (−0.39, −0.17) 5.19 × 10−7
10 rs12722517 6081040 Intron 1 C 330 −0.24 (−0.34, −0.14) 2.23 × 10−6
10 rs9663421 6055604 Intron 7 T 330 0.25 (0.15, 0.35) 3.17 × 10−6
10 rs12722553 6071284 Intron 1 A 330 −0.26 (−0.37, −0.15) 3.30 × 10−6
10 rs12722551 6071379 Intron 1 T 330 −0.26 (−0.37, −0.15) 3.30 × 10−6
10 rs791593 6083292 Intron 1 G 330 −0.23 (−0.33, −0.14) 4.22 × 10−6
10 rs2104286 6099045 Intron 1 C 330 −0.24 (−0.33, −0.14) 4.63 × 10−6
10 rs41294713 6080354 Intron 1 C 330 −0.25 (−0.36, −0.15) 5.23 × 10−6
10 rs12722515 6081230 Intron 1 A 330 −0.25 (−0.36, −0.15) 5.23 × 10−6
10 rs791590 6090322 Intron 1 T 330 −0.25 (−0.36, −0.15) 5.23 × 10−6
10 rs2246031 6092210 Intron 1 T 330 −0.25 (−0.36, −0.15) 5.23 × 10−6
10 rs7078614 6075831 Intron 1 T 330 −0.21 (−0.30, −0.12) 5.50 × 10−6
10 rs7920946 6074634 Intron 1 C 330 −0.22 (−0.31, −0.13) 5.53 × 10−6
10 rs4625363 6072504 Intron 1 G 330 −0.25 (−0.36, −0.15) 5.54 × 10−6
10 rs12722527 6077328 Intron 1 T 330 −0.25 (−0.36, −0.15) 5.54 × 10−6
10 rs12722523 6078390 Intron 1 A 330 −0.25 (−0.36, −0.15) 5.54 × 10−6
10 rs12722561 6069893 Intron 1 T 330 −0.25 (−0.36, −0.15) 6.22 × 10−6
10 rs12722559 6070273 Intron 1 A 330 −0.25 (−0.36, −0.15) 6.22 × 10−6
10 rs12722606 6053133 Exon 8 A 330 0.25 (0.14, 0.36) 6.98 × 10−6
10 rs11256335 6055222 Intron 7 A 330 0.25 (0.14, 0.36) 6.98 × 10−6
10 rs12722605 6053163 Exon 8 A 330 0.29 (0.17, 0.42) 7.27 × 10−6
10 rs12722497 6095928 Intron 1 A 330 0.35 (0.20, 0.50) 1.22 × 10−5
10 rs11256464 6082558 Intron 1 T 330 0.32 (0.18, 0.47) 2.55 × 10−5
10 rs11597237 6079017 Intron 1 T 330 −0.23 (−0.33, −0.12) 3.07 × 10−5
10 rs11256416 6075359 Intron 1 T 330 −0.21 (−0.31, −0.11) 3.67 × 10−5
10 rs7910961 6077796 Intron 1 T 330 0.20 (0.11, 0.30) 4.04 × 10−5
10 rs4747837 6058735 Intron 7 G 330 −0.23 (−0.34, −0.12) 4.34 × 10−5
10 rs7900385 6062748 Intron 4 A 330 −0.23 (−0.34, −0.12) 4.34 × 10−5
10 rs12722588 6060433 Intron 6 T 330 −0.22 (−0.33, −0.11) 5.83 × 10−5
10 rs12722587 6060630 Intron 6 T 330 −0.22 (−0.33, −0.11) 5.83 × 10−5
10 rs7093069 6063319 Intron 4 T 330 −0.22 (−0.33, −0.11) 5.83 × 10−5
10 rs11816044 6074082 Intron 1 A 330 0.20 (0.10, 0.30) 8.91 × 10−5
10 rs7100984 6078539 Intron 1 A 330 0.20 (0.10, 0.30) 9.07 × 10−5
10 rs12722574 6066462 Intron 2 A 330 −0.20 (−0.29, −0.10) 9.63 × 10−5
10 rs4749894 6058323 Intron 7 G 330 0.22 (0.11, 0.33) 1.00 × 10−4
10 rs4749924 6082396 Intron 1 C 330 0.20 (0.10, 0.29) 1.00 × 10−4
10 rs6602398 6082953 Intron 1 T 330 0.20 (0.10, 0.29) 1.00 × 10−4
10 rs7900744 6065611 Intron 3 G 330 −0.20 (−0.29, −0.10) 1.19 × 10−4
10 rs791588 6089342 Intron 1 G 330 0.15 (0.06, 0.24) 7.71 × 10−4
10 rs11256342 6057231 Intron 7 G 330 0.17 (.07, 0.26) 8.37 × 10−4
10 rs12253981 6092346 Intron 1 G 330 0.16 (0.07, 0.25) 8.84 × 10−4
10 rs2025345 6067688 Intron 2 G 330 0.16 (0.07, 0.26) 9.75 × 10−4
10 rs12358961 6066195 Intron 3 A 330 0.16 (0.07, 0.26) 1.03 × 10−3
10 rs1924138 6096158 Intron 1 A 330 0.16 (0.06, 0.25) 1.06 × 10−3
10 rs11256497 6087794 Intron 1 A 330 0.15 (0.06, 0.25) 1.36 × 10−3
10 rs10795752 6072354 Intron 1 T 330 0.15 (0.06, 0.25) 1.51 × 10−3
10 rs2245675 6095577 Intron 1 A 330 0.16 (0.06, 0.25) 1.55 × 10−3
10 rs2256852 6096923 Intron 1 A 330 0.16 (0.06, 0.25) 1.55 × 10−3
10 rs791587 6088699 Intron 1 A 330 0.14 (0.05, 0.23) 1.62 × 10−3
10 rs12251836 6091281 Intron 1 A 330 0.15 (0.06, 0.24) 1.65 × 10−3
10 rs6602368 6062915 Intron 4 C 330 0.15 (0.06, 0.24) 1.67 × 10−3
10 rs2476491 6095410 Intron 1 T 330 0.16 (0.06, 0.26) 1.74 × 10−3
10 rs4749926 6085312 Intron 1 A 330 0.15 (0.05, 0.24) 2.60 × 10−3
10 rs11256457 6080794 Intron 1 G 330 0.15 (0.05, 0.24) 2.72 × 10−3
10 rs10905641 6072293 Intron 1 C 330 0.14 (0.05, 0.23) 3.41 × 10−3
10 rs6602379 6073374 Intron 1 G 330 0.14 (0.05, 0.24) 3.51 × 10−3
10 rs809356 6091148 Intron 1 C 330 0.13 (0.04, 0.22) 3.60 × 10−3
10 rs2256774 6097165 Intron 1 C 330 0.14 (0.05, 0.23) 3.87 × 10−3
10 rs1323657 6072427 Intron 1 A 330 0.13 (0.04, 0.23) 3.95 × 10−3
10 rs7072398 6079846 Intron 1 A 330 0.13 (0.04. 0.22) 5.33 × 10−3
10 rs10795763 6096199 Intron 1 G 330 0.13 (0.04. 0.22) 5.34 × 10−3
10 rs7917726 6096600 Intron 1 G 330 0.13 (0.04. 0.22) 5.34 × 10−3
10 rs706779 6098824 Intron 1 C 330 0.12 (0.03. 0.21) 7.97 × 10−3
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Keindl et al. Increased sIL-2R in T1D Complicationsa shift from naïve to effector T cells (CD4+ and CD8+) in PBMCs
from T1D patients with vascular complications compared to
those without.
Since we observed significant differences in plasma sIL-2R in
the two PROLONG groups, we also investigated cell surface
expression of interleukin-2 receptor alpha (CD25) on PBMCs.
Remarkably, we did not see differences between NPs and
progressors in neither CD25+ T cells (p = 0.84) nor Tregs
(CD3+CD4+CD25++CD127-) (p = 0.27) (Supplementary
Figures 7A, B).DISCUSSION
The present study revealed that plasma sIL-2R levels are
reproducibly elevated in individuals with long-term T1D with
severe vascular complications as compared to those who
remained free from to vascular complications despite more
than 30 years of diabetes duration. Further, plasma levels of
sIL-2R were associated with SNPs in the IL2RA and PTPN2 gene
regions, which might suggest underlying genetic determinants
and possibly biological causal inference. Finally, our results are in
agreement with published studies confirming an increase of
circulating sIL-2R in patients with T1D when compared to
healthy controls, which might further emphasize that immune
factors contributing to diabetes pathogenesis might early on
govern progression to vascular complications (12, 23).
The biological function of sIL-2R is not yet completely
understood, but there is evidence that it reflects an imbalance
in Treg and effector T cell (TEFF) activity (14, 24). It has been
suggested that there is a reduced immunosuppressive function of
Tregs due to impaired IL-2 signalling in T1D (24–28), a defect
which may subsequently lead to a more aggressive immune
destruction of pancreatic b cells by TEFF (12, 28). In addition,
defects in the intracellular IL-2 pathways and a decreased
regulatory function have recently been reported in patients
with type 2 diabetes (T2D) (29). In many autoimmune
diseases, such as multiple sclerosis (MS) (30), rheumatoid
arthritis (31), primary Sjögren’s syndrome (32), scleroderma
(33), and inflammatory myopathies (34), but also in various
cancers (31), sIL-2R has been proposed to be a biomarker for
disease activity.
Patients with T1D develop the disease at an early age and a
large proportion of them will progress to devastating vascular
complications representing a major problem because the tools
for monitoring when and how disease deteriorates are notFrontiers in Endocrinology | www.frontiersin.org 8available (4). Diabetes retinopathy is the most common
vascular complication of diabetes (35) and the proliferative
form of diabetic retinopathy (PDR) is the leading cause of
vision loss in adults (36). Previous studies show that several
inflammatory cytokines are involved in the pathogenesis and
progression of PDR, including sIL-2R (19), however, not all of
the results have been replicated. In the present study, both
PROLONG and DIALONG progressors with PDR had higher
plasma levels of sIL-2R compared to NPs, supporting the notion
that sIL-2R could emerge as a contributing player not only in the
pathogenesis of T1D but also in disease progression.
An additional evidence in the present study to biological
importance of sIL-2R were our findings that 68 IL2RA SNPs are
associated with sIL-2R plasma levels in PROLONG patients with
T1D and correlated with the elevated sIL-2R levels observed in
progressors accordingly. IL2RA rs12722489 showed the strongest
association with sIL-2R plasma levels in patients with T1D and is
located in the large intron 1. This particular SNP has been
identified as a risk factor for MS in several studies (37–39).
However, a secondary association was suggested due to the
nearby location of rs2104286 (Linkage disequilibrium D’ = 1,
R2 = 0.58), which is a well-recognized T1D risk factor (11, 37)
and also significantly associated with plasma sIL-2R in our
dataset. Interestingly, one of our identified SNPs, rs2256774,
was associated with higher levels of Rubella antibodies (40), and
Rubella viral infections have been associated with the onset of
T1D (41, 42). Additionally, multiple IL2RA variants have been
shown to correlate with sIL-2R levels in T1D (10) and MS (37)
and IL2RA gene variants are associated with susceptibility of
T1D (10, 11, 43). Further, functional studies support these results
by suggesting that specific IL2RA variants cause defects in
immune homeostasis due to impaired IL-2 signalling in Tregs
(25, 27, 44).
Interestingly, seventeen of our identified SNPs are positioned
within the first 15 kb of the first intron of the IL2RA gene, which
has been described as a super-enhancer region due to a cluster of
histone 3 lysine 27 acetylation (H3K27ac) elements in this area
(45). Notably, many of the IL2RA SNPs related to autoimmune
diseases fall into this region and affect transcription factor
binding and enhancer activity (46). Several of our identified
SNPs have been reported to be associated with DNAmethylation
at the IL2RA promoter locus, particularly rs6602398 and
rs4749926 (47). Despite having detected a number of IL2RA
SNPs to be associated with sIL-2R, it is challenging to conclude
the direct effect of those mostly intronic SNPs on the expression
of IL-2R itself and in-depth research is scarce. However, it hasTABLE 3 | Continued
Chr SNP bp* Intron/Exon A1 n Beta (95% CI) p-Value
10 rs10905656 6086093 Intron 1 A 330 0.11 (0.02. 0.20) 1.51 × 10−2
10 rs3793713 6059704 Intron 7 G 330 0.11 (0.01. 0.20) 2.56 × 10−2
10 rs4749920 6071453 Intron 1 C 330 0.11 (0.01. 0.21) 3.73 × 10−2
10 rs4749921 6071654 Intron 1 C 330 0.11 (0.01. 0.21) 3.73 × 10−2
10 rs4747845 6074441 Intron 1 A 330 0.11 (0.01. 0.21) 3.73 × 10−2October 2020 | Volume 11 | Ar*SNP positions according to the Genome Reference Consortium Human Build 37 (GRch37).
Linear regression model: p-value = adjusted for age, sex and complication group. Chr, chromosome; SNP, single nucleotide polymorphism; bp, base pair; A1, minor allele; CI, confidence interval.ticle 575469
Keindl et al. Increased sIL-2R in T1D Complicationsbeen reported that one of our identified SNPs, rs12251836, is
associated with IL2RA expression on acutely triggered TEFF, but
not in Tregs (48), suggesting a likely biological causal inference of
IL-2R gene locus in T1D.
Another exciting and supporting genetic observation
included 53 PTPN2 SNPs to be significantly associated withFrontiers in Endocrinology | www.frontiersin.org 9sIL-2R plasma levels, importantly 42 of which were associations
independent of IL2RA variant rs2104286. Our most significant
SNP in PTPN2 is rs12971201, which has previously been
associated with T1D, however a secondary association has been
suggested due to rs1893217 (49). This particular variant is
considered a risk variant for T1D and celiac disease (50, 51),TABLE 4 | Imputed PTPN2 genotypes and their significant associations with sIL-2R in plasma.
Chr SNP bp* Intron/Exon A1 n Beta (95% CI) p-Valuea p-Valueb
18 rs12971201 12830538 Intron 4 A 330 0.16 (0.07, 0.26) 1.09 × 10−3 3.01 × 10−3
18 rs2542162 12820900 Intron 5 T 330 0.16 (0.06, 0.26) 1.13 × 10−3 2.91 × 10−3
18 rs2847281 12821593 Intron 5 G 330 0.16 (0.06, 0.26) 1.13 × 10−3 2.91 × 10−3
18 rs2852151 12841176 Intron 2 A 330 0.16 (0.06, 0.26) 1.16 × 10−3 3.38 × 10−3
18 rs3826557 12843263 Intron 2 T 330 0.16 (0.06, 0.26) 1.16 × 10−3 3.38 × 10−3
18 rs674222 12848349 Intron 2 C 330 0.16 (0.06, 0.26) 1.16 × 10−3 3.38 × 10−3
18 rs2847273 12856908 Intron 2 C 330 0.16 (0.06, 0.26) 1.16 × 10−3 3.38 × 10−3
18 rs641085 12824930 Intron 5 T 330 0.15 (0.06, 0.24) 1.61 × 10−3 2.22 × 10−3
18 rs592390 12822314 Intron 5 C 330 0.15 (0.06, 0.24) 1.67 × 10−3 2.16 × 10−3
18 rs12957037 12829065 Intron 4 G 330 0.15 (0.06, 0.24) 1.67 × 10−3 2.16 × 10−3
18 rs588447 12832842 Intron 3 C 330 0.15 (0.06, 0.24) 1.69 × 10−3 2.48 × 10−3
18 rs8087237 12834359 Intron 3 A 330 0.15 (0.06, 0.24) 1.69 × 10−3 2.48 × 10−3
18 rs478582 12835976 Intron 3 C 330 0.15 (0.06, 0.24) 1.69 × 10−3 2.48 × 10−3
18 rs559406 12857002 Intron 2 G 330 −0.14 (−0.24, −0.05) 1.94 × 10−3 2.44 × 10−3
18 rs960550 12827697 Intron 4 T 330 0.15 (0.06, 0.25) 2.08 × 10−3 6.02 × 10−3
18 rs4797709 12882359 Intron 1 C 330 0.15 (0.05, 0.24) 2.43 × 10−3 6.64 × 10−3
18 rs2292759 12884343 upstream A 330 0.15 (0.05, 0.24) 2.43 × 10−3 8.09 × 10−3
18 rs2542157 12787247 Intron 10 G 330 0.14 (0.04, 0.23) 5.57 × 10−3 4.98 × 10−3
18 rs2847291 12808713 Intron 8 A 330 0.14 (0.04, 0.24) 6.86 × 10−3 1.43 × 10−2
18 rs11663472 12810471 Intron 8 A 330 0.14 (0.04, 0.24) 6.86 × 10−3 1.43 × 10−2
18 rs2847286 12817815 Intron 6 G 330 0.14 (0.04, 0.24) 6.86 × 10−3 1.43 × 10−2
18 rs2847285 12818224 Intron 6 A 330 0.14 (0.04, 0.24) 6.86 × 10−3 1.43 × 10−2
18 rs45456495 12792228 Intron 10 T 330 0.13 (0.03, 0.24) 9.11 × 10−3 1.77 × 10−2
18 rs2542167 12795849 Intron 9 T 330 0.13 (0.03, 0.24) 9.11 × 10−3 1.77 × 10−2
18 rs2847298 12800120 Intron 9 G 330 0.13 (0.03, 0.24) 9.11 × 10−3 1.77 × 10−2
18 rs2542160 12789246 Intron 10 C 330 0.13 (0.03, 0.23) 1.06 × 10−2 1.94 × 10−2
18 rs2847299 12801337 Intron 9 A 330 0.14 (0.03, 0.24) 1.10 × 10−2 3.06 × 10−2
18 rs7227207 12819616 Intron 5 T 330 −0.13 (−0.23, −0.03) 1.15 × 10−2 2.13 × 10−2
18 rs72872125 12876915 Intron 1 T 330 0.19 (0.04, 0.34) 1.24 × 10−2 1.72 × 10−2
18 rs60474474 12792736 Intron 10 T 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs45450798 12792940 Intron 10 G 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs60751993 12795420 Intron 9 A 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs60735058 12795470 Intron 9 A 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs8096138 12808140 Intron 8 G 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs1893217 12809340 Intron 8 G 330 −0.14 (−0.25, −0.03) 1.68 × 10−2 2.03 × 10−2
18 rs11663253 12789556 Intron 10 G 330 −0.13 (−0.25, −0.02) 1.84 × 10−2 2.12 × 10−2
18 rs10502416 12822702 Intron 5 T 330 −0.13 (−0.24, −0.02) 2.01 × 10−2 2.14 × 10−2
18 rs78637414 12826836 Intron 4 A 330 −0.13 (−0.24, −0.02) 2.01 × 10−2 2.14 × 10−2
18 rs62097820 12834649 Intron 3 T 330 −0.13 (−0.24, −0.02) 2.01 × 10−2 2.14 × 10−2
18 rs8096327 12887750 Upstream G 330 −0.10 (−0.19, −0.01) 2.91 × 10−2 3.71 × 10−2
18 rs3737361 12831324 Intron 3 C 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−2
18 rs16939910 12837993 Intron 2 A 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−2
18 rs3786158 12843275 Intron 2 A 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−2
18 rs11080605 12847329 Intron 2 C 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−2
18 rs62097858 12862581 Intron 1 A 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−−2
18 rs8091720 12865186 Intron 1 T 330 −0.11 (−0.22, −0.01) 3.07 × 10−2 5.45 × 10−2
18 rs7244152 12854294 Intron 2 C 330 −0.11 (−0.22, −0.01) 3.23 × 10−2 5.44 × 10−2
18 rs11080606 12867969 Intron 1 C 330 −0.11 (−0.22, −0.01) 3.23 × 10−2 5.44 × 10−2
18 rs7242788 12820330 Intron 5 A 330 −0.11 (−0.22, −0.01) 3.30 × 10−2 5.79 × 10−2
18 rs12959799 12900695 Upstream G 330 0.11 (0.01, 0.21) 4.01 × 10−2 5.41 × 10−2
18 rs80262450 12818922 Intron 6 A 330 −0.13 (−0.25, −0.01) 4.13 × 10−2 3.45 × 10−2
18 rs56946650 12916943 Upstream T 330 −0.11 (−0.22, −0.00) 4.16 × 10−2 6.45 × 10−2
18 rs2847282 12819820 Intron 5 G 330 −0.09 (−0.19, −0.00) 4.79 × 10−2 6.62 × 10−2October 2020 | Volume 11 | A*SNP positions according to the Genome Reference Consortium Human Build 37 (GRch37)
Linear regression models: p-valuea = adjusted for age, sex and complication group; p-valueb = adjusted for age, sex, complication group and rs2104286. Chr, chromosome; SNP, single
nucleotide polymorphism; bp, base pair; A1, minor allele; CI, confidence interval.rticle 575469
Keindl et al. Increased sIL-2R in T1D Complicationsand correlated with impaired IL-2 signalling in CD4+ T cells as
measured by decreased phosphorylation of STAT5 (pSTAT5)
but also reduced PTPN2 expression (52). One of our identified
SNPs, rs2847281, was shown to significantly associate with CRP
levels along many other PTPN2 variants (53). PTPN2 is a
negative regulator in the IL-2 signalling cascade and several
SNPs in the PTPN2 gene region have been linked to different
autoimmune diseases including T1D, rheumatoid arthritis and
Crohn’s disease (54, 55). Furthermore, different genetic variants
in PTPN2 were reported to be associated with diminished IL-2
responsiveness in naïve Tregs from patients with long-standing
T1D (56). PTPN2 has been shown to modulate interferon
gamma signal transduction in pancreatic b cells and regulate
cytokine-induced apoptosis, which could potentially contribute
to the pathogenesis of T1D (57).
As described above, elevated sIL-2R levels are likely to reflect
an imbalance in Treg and TEFF activity. PBMCs from PROLONG
patients with T1D with vascular complications displayed a shift
from naïve T cells (TN) to TEFF, however, we cannot distinguish
whether this shift is the cause or the result of diabeticFrontiers in Endocrinology | www.frontiersin.org 10complications. The interpretation of these results was difficult
due to the small and heterogeneous sample size in the progressors
group. One can speculate that progressors have increased TEFF
due to impaired Treg suppression leading to a more destructive
form of T1D, thereby more active course of the disease. This
systemic long-term inflammation could subsequently drive the
development of vascular complications by affecting tissues aside
from the pancreas. Further studies testing suppression capacity of
Tregs isolated from patients with T1D with and without
complications are crucial to confirm this notion.
In PROLONG, we observed significantly higher levels of sIL-
2R in progressors which associated with IL2RA SNPs, however
the surface expression of IL-2R on circulating immune cells was
similar between progressors and NPs. This may be confirmatory
for the theory that it is not the number of cells expressing IL-2R
making a difference, but the efficiency of IL-2 signalling within
the cells themselves. Paradoxically, the IL-2/IL-2R signalling
pathway is important in immunity and tolerance, which is
further complicated by shedding of sIL-2R. How sIL-2R is
involved in the pathogenesis of different diseases remains aA B
C D
FIGURE 2 | Patients with type 1 diabetes (T1D) with complications display a shift from naïve T cells to effector T cells. (A) Flow cytometry screening of PBMCs from
PROLONG patients revealed a significant decrease of CD8+ naïve T (TN) cells (CD3
+CD4+CD45RA+CCR7+CCR5-) in progressors (P) compared to non-progressors (NP).
(B) Progressors displayed elevated CD8+ effector T (TEFF) cells (CD3
+CD4+CD45RA+CCR7-) simultaneously (p = ns). (C) CD4+ TN cells were also declined in patients with T1D
with complications as compared to NPs (p = ns). (D) In progressors CD4+ TEFF cells were significantly elevated compared to NPs. (For the comparison between the different
groups, multiple linear regression was applied and adjusted for the age and sex covariates. *p < 0.05 and **p < 0.01).October 2020 | Volume 11 | Article 575469
Keindl et al. Increased sIL-2R in T1D Complicationspuzzle. The high-affinity receptor for IL-2 consists of 3 protein
chains, namely IL-2Ra, IL-2Rb, and IL-2Rg. Upon proteolytic
cleavage of the ectodomains of the membrane-bound IL-2Ra
and release into the extracellular space, sIL-2R retains the ability
to bind IL-2 with low affinity, which can lead to different
outcomes. Firstly, sIL-2R may function as a decoy-receptor
reducing the bioavailability of IL-2 and favor tolerance
controlled by Tregs over immunity. Tregs constitutively
express the high-affinity IL-2R, which enables them to out-
compete conventional T cells with the intermediate-affinity
receptor (IL-2Rb and IL-2Rg) when less IL-2 is available,
thereby boosting immune tolerance (58). This difference in
affinity is exploited in clinical trials in T1D where the
administration of low-dose IL-2 has shown promising effects
expanding and activating Tregs (59, 60). Alternatively, the
binding of sIL-2R to IL-2 can enable in trans presentation of
IL-2 to T-cells which only express the intermediate-affinity IL-
2R. Overall, increased shedding of sIL-2R and it binding to IL-2
can have opposing effects depending on the cell type
affected (58).
Stratified analysis of different vascular complications revealed
increased sIL-2R and CCL2 levels in DIALONG patients with
CVD in comparison to patients with T1D with other diabetic
complications. Elevated sIL-2R has been described as a marker
for coronary artery calcification progression in both individuals
with and without T1D independent of traditional CVD risk
factors (20). CCL2 plays a critical role in the development of
atherosclerotic plaque formation by attracting monocytes to the
vessel lumen where they will differentiate into macrophages and
become foam cells by the uptake of low-density lipoprotein (61).
Elevated plasma levels of CCL2 have also been associated with
CVD (61–63). The observed increases in sIL-2R and CCL2 were
based on a small sample set in DIALONG, however, the patient
characterisation for CVD was performed thoroughly using
computed tomography coronary angiography, which enabled
the identification of asymptomatic coronary artery disease (64).
Nevertheless, we were not able to investigate this finding in
PROLONG due to the limited information on CVD.
Previously it was shown in the EURODIAB study that
patients with T1D with complications have increased IL-6 and
TNF-a as compared to individuals without complications (9).
We could neither confirm nor confound this finding due to the
low detection rate of IL-6 and TNF-a (< 20%) in our study,
which statistically did not allow for reliable comparisons. In
general, the detection rates in our cytokine screening were
considerably low, where many of the investigated biomarkers
were not detected at all. This could be due to technical differences
and kit quality, however all kits used were validated for plasma
usage by the respective providers, we followed manufacturer’s
instructions accordingly and did not experience technical issues
during analysis.
Our future perspective is to unravel the role of IL-2R in the
progression to diabetic complications in general, larger cohorts
analyzing sIL-2R levels in other types of diabetes, such as T2D
with no autoimmunity and latent autoimmune diabetes of adults,
are of importance. To investigate the predictive power of sIL-2RFrontiers in Endocrinology | www.frontiersin.org 11levels in the development of diabetic complications, longitudinal
studies in children and adolescents would be a great asset.
Furthermore, it is of great interest to study the relationship
between sIL-2R and IL-2 signalling efficacy and Treg function in
patients with T1D.
In summary, we conclude that IL2RA and PTPN2 gene
variants may not only increase the risk of T1D, but in addition
the development of diabetic complications possibly by
influencing sIL-2R plasma levels and lowering T cell
responsiveness. Thus, sIL-2R could potentially act as a
biomarker for monitoring vascular complications in people
with T1D thereby enabling early treatment and improving
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